Pharmaceutical development and clinical manufacturing company, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, MI.
 
The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities. This facility will be supported by Velesco Pharma’s existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the company’s existing manufacturing site in Kalamazoo, MI.
 
As part of the expansion, the company has continued to invest in its growing team  with the recent promotion of two senior leaders. Peter Angus has moved into the role of vice president of research while Lisa Crandall is now vice president of development. Both have been with Velesco Pharma since its inception.
 
Founded in 2007, Velesco Pharma supports early and later stage drug development through contract analytical and drug formulation services, along with cGMP clinical supplies offering a full range of non-sterile dosage forms.
 
“This investment in new space and increase in our capacity will enable us to meet growing client demands for cGMP clinical manufacturing services while still maintaining our science-focus and flexible approach to client projects,” said Dave Barnes, chief executive officer, Velesco Pharma. “Our team forged their careers in big pharma R&D and bring a wealth of expertise to the table. This experience combined with our personalized and agile approach makes us an ideal choice for clients in the critical early and later stage drug development phases.
 
The new facility is set to be fully operational by the end of this year.